<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.125877.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>General anaesthetics reduce acute lymphoblastic leukaemia cell migration and homing 
                    <italic>in vitro</italic> and
                    <italic> in vivo</italic> 
                    <italic>via</italic> CXCR4 and osteopontin mediated mechanisms</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 2 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Jiang</surname>
                        <given-names>Cui</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-4789-8386</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Gonzalez-Anton</surname>
                        <given-names>Sara</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                    <xref ref-type="aff" rid="a3">3</xref>
                    <xref ref-type="aff" rid="a4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Li</surname>
                        <given-names>Xiaomeng</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Mi</surname>
                        <given-names>Emma</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Wu</surname>
                        <given-names>Lingzhi</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Zhao</surname>
                        <given-names>Hailin</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Zhang</surname>
                        <given-names>Ge</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a5">5</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Lu</surname>
                        <given-names>Aiping</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a5">5</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Lo Celso</surname>
                        <given-names>Cristina</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Funding Acquisition</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a2">2</xref>
                    <xref ref-type="aff" rid="a3">3</xref>
                    <xref ref-type="aff" rid="a4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Ma</surname>
                        <given-names>Daqing</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-1235-0537</uri>
                    <xref ref-type="corresp" rid="c2">b</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Division of Anaesthetics, Pain Medicine and Intensive Care, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, SW10 9NH, UK</aff>
                <aff id="a2">
                    <label>2</label>Department of Life Sciences, Imperial College London, South Kensington Campus, Imperial College London, London, SW7 2AZ, UK</aff>
                <aff id="a3">
                    <label>3</label>Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, NW1 1AT, UK</aff>
                <aff id="a4">
                    <label>4</label>Lo Celso Laboratory, The Francis Crick Institute, London, UK</aff>
                <aff id="a5">
                    <label>5</label>School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:c.lo-celso@imperial.ac.uk">c.lo-celso@imperial.ac.uk</email>
                </corresp>
                <corresp id="c2">
                    <label>b</label>
                    <email xlink:href="mailto:d.ma@imperial.ac.uk">d.ma@imperial.ac.uk</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>12</day>
                <month>12</month>
                <year>2022</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2022</year>
            </pub-date>
            <volume>11</volume>
            <elocation-id>1491</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>1</day>
                    <month>11</month>
                    <year>2022</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2022 Jiang C et al.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/11-1491/pdf"/>
            <abstract>
                <p>
                    <italic toggle="yes">Background</italic>
                </p>
                <p>Acute lymphoblastic leukaemia (ALL) is the most common type of cancer in children. General anaesthetics are often used on patients undergoing painful procedures during ALL treatments but their effects on ALL malignancy remain unknown. Herein, we aim to study the effect of two commonly used general anaesthetics, intravenous propofol and inhalational sevoflurane, on the migration and homing of ALL cells 
                    <italic toggle="yes">in vitro</italic> and 
                    <italic toggle="yes">in vivo.</italic>
                </p>
                <p>
                    <italic toggle="yes">Methods</italic>
                </p>
                <p>NALM-6 cells were treated with propofol (5 and 10 &#x03bc;g/ml) or sevoflurane (3.6%) 
                    <italic toggle="yes">in vitro</italic> for six hours. Then, cells were harvested for flow cytometry analysis. For 
                    <italic toggle="yes">in vitro</italic> migration experiments, NALM-6 cells were pre-treated with propofol and sevoflurane for six hours before being loaded onto the upper chamber of a migration chamber and cells were collected in the lower chamber after six hours of migration. For 
                    <italic toggle="yes">in vitro</italic> adhesion assays, NALM-6 cells were pre-treated with propofol and sevoflurane before an adhesion assay was carried out. 
                    <italic toggle="yes">For in vivo</italic> experiments, GFP-NALM-6 cells were pre-treated with propofol (10 &#x03bc;g/ml) or sevoflurane (3.6%) for six hours. Then, cells were injected intravenously into C57BL/6 female mice followed by intravital microscopy.</p>
                <p>
                    <italic toggle="yes">Results</italic>
                </p>
                <p>Both anaesthetics reduced 
                    <italic toggle="yes">in vitro</italic> migration, 
                    <italic toggle="yes">in vivo</italic> migration and 
                    <italic toggle="yes">in vivo</italic> homing, as exemplified by 1) the reduction in the number of cells entering the bone marrow and 2) the disturbance in homing location in relation to the nearest endosteal surface. Our results indicated that general anaesthetics reduced the surface CXCR4 expression. In addition, the adhesion of leukaemia cells to thrombin cleaved osteopontin (OPN) was reduced by general anaesthetics. Those changes might result in the alterations in migration and homing.</p>
                <p>
                    <italic toggle="yes">Conclusion</italic>
                </p>
                <p>Together, our data suggest that&#x00a0;both propofol and sevoflurane could reduce ALL migration and homing 
                    <italic toggle="yes">in vivo</italic> and 
                    <italic toggle="yes">in vitro via</italic> CXCR4 and OPN mediated mechanisms.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>General anaesthetics</kwd>
                <kwd>Propofol</kwd>
                <kwd>Sevoflurane</kwd>
                <kwd>Acute lymphoblastic leukaemia</kwd>
                <kwd>Migration</kwd>
                <kwd>Homing</kwd>
            </kwd-group>
            <funding-group>
                <award-group id="fund-1">
                    <funding-source>Royal College of Anaesthetists</funding-source>
                </award-group>
                <award-group id="fund-2">
                    <funding-source>UK and European Research Council</funding-source>
                    <award-id>STG337066</award-id>
                </award-group>
                <award-group id="fund-3">
                    <funding-source>Cancer Research UK</funding-source>
                    <award-id>C36195/A26770</award-id>
                </award-group>
                <funding-statement>Royal College of Anaesthetists, London, UK and European Research Council (STG 337066), Brussels, Belgium and Cancer Research UK (C36195/A26770), London, UK. </funding-statement>
                <funding-statement>
                    <italic>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</italic>
                </funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec1">
            <title>Background</title>
            <p>Leukaemia is the most common cancer in children, accounting for approximately one third of all childhood cancers, and the vast majority of cases (78%) are acute lymphoblastic leukaemia (ALL). ALL is the main cause of death before the age of 20 in the young with cancer.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup> During ALL treatments, patients repeatedly receive painful and anxiety-inducing procedures, including bone marrow biopsy, bone marrow harvest, insertion of central lines, and intrathecal chemotherapy. Young patients generally cannot tolerate these procedures under local anaesthesia alone and normally require general anaesthesia. Additionally, general anaesthesia is often required to facilitate radiotherapy procedures, to ensure immobilization in young children. Therefore, paediatric patients frequently receive anaesthetics when invasive procedures are essential for diagnosis, treatment, and disease monitoring throughout treatment cycles from the induction phase to the surveillance phase, thus providing several opportunities for anaesthetics to have potential effects (if any) on leukaemia cells.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
            </p>
            <p>It has been long assumed that the behavioural and systematic effects of general anaesthetics are entirely reversible and that the central nervous system (CNS) and whole body completely recover once the anaesthetic agent is eliminated from the body. However, an increasing number of studies have shown that anaesthetics can cause long lasting effects. For example, our group firstly found that xenon (an inhalational general anaesthetic) protects the kidney against ischemia-refusion injury by upregulating hypoxia-inducible factor-1
                <italic toggle="yes">&#x03b1;</italic> (HIF-1
                <italic toggle="yes">&#x03b1;</italic>).
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup> Following this discovery, other inhalational general anaesthetics like isoflurane have been shown to enhance cancer malignancy by enhancing angiogenesis, migration, invasion, and proliferation 
                <italic toggle="yes">in vitro.</italic>
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> In line with 
                <italic toggle="yes">in vitro</italic> findings, recent retrospective clinical data have shown an association between inhalational general anaesthesia and reduced long-term survival in cancer patients undergoing elective surgery.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup> Taken together, this evidence suggests that anaesthetics used during procedures may affect cancer outcomes; however, this warrants further investigation.</p>
            <p>Migration, homing, and subsequent adhesion of leukaemia cells to a specific niche in the bone marrow are vital in leukaemogenesis, propagation of the disease, and chemoresistance. The chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) and its ligand stromal-cell-derived factor 1 (SDF-1, also known as CXCL12) mediates the homing and migration process in ALL.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup> Sipkins 
                <italic toggle="yes">et al</italic>. demonstrated that B-ALL cells selectively homed to adhesion molecule E-selectin and SDF-1-expressing vessels 
                <italic toggle="yes">via</italic> a CXCR4-dependent process. Disruption of the interaction between SDF-1 and CXCR4 inhibited the homing and migration process.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup> Osteopontin (OPN) is an adhesive glycoprotein mainly secreted by osteoblasts and serves complex functions in bone marrow. Several isoforms of OPN exist in bone marrow due to cleavage by thrombin
                <sup>
                    <xref ref-type="bibr" rid="ref9">9</xref>
                </sup> and are associated with different functions. In particular, thrombin-cleaved OPN could act as an adhesion molecule for leukaemia cells in the bone marrow.
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup>
            </p>
            <p>We hypothesized that general anaesthetics may affect the migration and homing of ALL cells by impacting CXCR4 and OPN-mediated mechanisms. The present study, therefore, aims to investigate the impact of two commonly used general anaesthetics (propofol and sevoflurane) on leukaemia cell homing and migration by using a well-established ALL cell line (NALM-6) 
                <italic toggle="yes">in vitro</italic> and an engineered GFP-NALM-6 cell line 
                <italic toggle="yes">in vivo.</italic>
            </p>
        </sec>
        <sec id="sec2" sec-type="methods">
            <title>Methods</title>
            <sec id="sec3">
                <title>Cell culture</title>
                <p>Human authenticated leukaemia NALM-6 cells, RRID:CVCL_0092 were cultured in T175 tissue culture flasks (VWR, Leicestershire, UK). They were maintained at 37&#x00b0;C in humidified air balanced with 5% CO
                    <sub>2</sub> in RPMI 1640 medium (GIBCO, Invitrogen, Paisley, UK) supplemented with 10% heat-inactivated fetal calf serum (Thermo Scientific, Epsom, UK), 2 mM L-glutamine and 100 U ml
                    <sup>-1</sup> penicillin-streptomycin (Invitrogen). Culture medium was replaced every day.</p>
            </sec>
            <sec id="sec4">
                <title>Sevoflurane exposure</title>
                <p>Before gas exposure, NALM-6 cells were cultured at 1 &#x00d7; 10
                    <sup>6</sup> per ml density on 30 mm
                    <sup>2</sup> Petri dishes (VWR, Leicestershire, UK), or 24-well plates with a seeding density of 5 &#x00d7; 10
                    <sup>4</sup> per ml. Cells were used 12 hours after seeding. Cells were placed in 1.5 L purpose-built airtight, temperature-controlled chambers equipped with inlet and outlet valves and an internal electric fan, which was used to provide a continuous delivery and mixture of gases. The chamber was connected to calibrated flow meters and an in-line vaporizer was used to deliver the desired composition (Datex gas monitor, Helsinki, Finland) of sevoflurane (3.6%, MAC 2.0) (Abbott Laboratories, Maidenhead, UK) in 21% oxygen and 5% CO
                    <sub>2</sub> balanced with nitrogen (BOC, Guildford, UK). The chamber was pre-flushed with the aforementioned gas mixture to ensure that a stable gas composition was achieved, and a closed system was established to prevent leakage. Gas treatment was given at the desired sevoflurane concentration for two, four, and six hours at 37&#x00b0;C. At the end of treatment, cells were harvested for further analysis. Cells used as the na&#x00ef;ve control group were placed in an identical gas chamber containing 21% oxygen and 5% CO
                    <sub>2</sub> balanced with nitrogen at 37&#x00b0;C.</p>
            </sec>
            <sec id="sec5">
                <title>Propofol treatment</title>
                <p>A clinical formulation of propofol was used. It was dissolved in 10% intralipid (Astra-Zeneca, London, UK). On the day of the experiment, the stock solution of propofol was diluted with medium to the desired concentrations (5 and 10 &#x03bc;g/ml, equivalent to 28 and 56 &#x03bc;M, respectively). For the intralipid control (vehicle control), 10% intralipid was added to the cell medium to recreate the amount of intralipid in the highest (10 &#x03bc;g/ml) dose of propofol being used. Propofol-supplemented medium was added to the cell cultures for six hours. At the end of treatment, cells were harvested for further analysis. Cells used as the na&#x00ef;ve control group were treated with identical medium with no propofol or intralipid.</p>
            </sec>
            <sec id="sec6">
                <title>Flow cytometry</title>
                <p>For cell surface receptor experiments, leukaemia cells were incubated with CXCR4 (eBiosciecne, 17-9999-42, APC) and CD49d (eBioscience, 12-0499-42, PE) antibodies for 30 minutes at 4&#x00b0;C. After incubation, cells were washed with PBS and samples were run on a flow cytometer (CyAn ADP; Beckman Coulter, US). In addition, isotype controls were used to establish background fluorescence signals including: 1) mouse IgG2a kappa isotype control eBM2a (eBioscience, 17-4724-81, APC) and 2) mouse IgG1 kappa isotype control P3.6.2.8.1 (eBioscience, 12-4714-82, PE). In order to gate cells, the scatter plot of forward scatter versus side scatter was initially gated to have 
                    <italic toggle="yes">via</italic>ble cells. Then, duplicates were excluded by plotting forward scatter height versus area. Finally, protein expression represented by mean fluoresce intensity (MFI) was recorded using a histogram. Each assay included 50,000 gated events. All samples were analysed 
                    <italic toggle="yes">via</italic> FlowJo software. For propidium iodide experiments, cells were stained with propidium iodide (e-Bioscience, 00-6990-50, PE-Texas red) and incubated in the dark at room temperature for 5 minutes. A count of 50,000 cells per sample were analysed with a flow cytometer (CyAn ADP; Beckman Coulter, US). In order to determine the cell death 
                    <italic toggle="yes">via</italic> propidium iodide, the scatter plot of forward scatter versus the PE-Texas was initially analysed in na&#x00ef;ve control samples to determine the population of healthy cells. We determined any cells with an intensity larger than 10
                    <sup>2</sup> in the PE-Texas red channel to be dead cells.</p>
            </sec>
            <sec id="sec7">
                <title>
                    <italic toggle="yes">In vitro</italic> migration assay</title>
                <p>
                    <italic toggle="yes">In vitro</italic> migration assay was performed by loading 2 &#x00d7; 10
                    <sup>5</sup> pre-treated cells into the upper chamber of the migration chamber. Cells were allowed to migrate for six hours before being collected in the lower chamber. The lower chamber was supplied with 20 ng/ml SDF-1 as a chemoattractant. Finally, samples were run on a flow cytometer (CyAn ADP; Beckman Coulter, US) with Accu check counting beads (Thermo Fisher, PCB 100, UK) to determine absolute cell counts in each sample.</p>
            </sec>
            <sec id="sec8">
                <title>
                    <italic toggle="yes">In vitro</italic> adhesion assay</title>
                <p>NALM-6 cells were pre-treated with propofol and sevoflurane with respective concentrations. Recombinant human OPN (R&amp;D systems, 1433-OP-050/CF) was thrombin-cleaved by incubating 24 &#x03bc;g recombinant full length human OPN in 20 mM Tris-HCL (pH7.6), 80 mM NaCl, 2 mM CaCl
                    <sub>2</sub>, and 0.1 unit thrombin (Merck, 10602400001) for ten minutes at 37 degrees. Then, full length OPN and thrombin-cleaved OPN were coated at 20 &#x03bc;g/ml the night before experiment. Then, 5 &#x00d7; 10
                    <sup>5</sup> cells of NALM-6 cells were labelled with calcein-AM stock solution from the Vybrant cell adhesion assay kit (ThermoFisher, UK). Pre-labelled NALM-6 cells were allowed to adhere for two hours under 37&#x00b0;C. Finally, fluorescence readings were read at 494 nm. The percentage of adhesion was determined by dividing the corrected (background subtracted) fluorescence of adherent cells by the total corrected fluorescence of cells added to each microplate well and multiplying by 100%.</p>
            </sec>
            <sec id="sec9">
                <title>Mouse study</title>
                <p>All animal work was in accordance with the animal ethics committee (AWERB) at Imperial College London, UK and the UK Home Office regulations (ASPA, 1986). C57BL/6 female mice were purchased from Charles rivers UK Ltd with minimum age &gt;6 weeks with weight around 20-22 g. All animals were allowed for 7 days of acclimation before procedures.</p>
                <p>Prior to procedures, animals were randomly allocated into three groups: 1) na&#x00ef;ve control group, 2) propofol treated group and 3) sevoflurane treated group. In na&#x00ef;ve control group, animals were given one million untreated GFP-NALM-6 cells through tail vein injection followed by intravital microscopy. In propofol and sevoflurane treated group, animals were given one million pre-treated GFP-NALM-6 cells (pre-treated with 10 &#x03bc;g/ml propofol and 3.6% sevoflurane for six hours 
                    <italic toggle="yes">in vitro</italic>, respectively) followed by intravital microscopy. On the day of experiments, we would normally do three intravital microscopy procedures in the order of 1) na&#x00ef;ve control group, 2) propofol treated group and 3) sevoflurane treated group to minimise potential confounders. All members involved in the mouse study were aware of group allocations at all stages.</p>
            </sec>
            <sec id="sec10">
                <title>GFP-expressing virus transduction</title>
                <p>Initially, 5 &#x00d7; 10
                    <sup>4</sup> of NALM-6 cells were seeded in a 24-well plate. After 12 hours, TransDux and TransDUX MAX enhancer (System Biosciences, Palo Alto, USA) were mixed and added to culture at a concentration of 1X. Then, pre-packed GFP lentivirus (System Biosciences, Palo Alto, USA) was added to NALM-6 cells at a multiplicity of infection (MOI) of 20. Cells were incubated in 5% CO
                    <sub>2</sub> at 37&#x00b0;C for 72 hours. Finally, GFP-expressing NALM-6 cells were sorted using FACS Aria-II cell sorter (BD, USA), before seeding in a T175 flask with fresh medium.</p>
            </sec>
            <sec id="sec11">
                <title>Intravital microscopy</title>
                <p>Intravital microscopy was performed using a Leica SP5 and a Zeiss LSM 780 upright confocal microscopes, both with a motorized stage.
                    <sup>
                        <xref ref-type="bibr" rid="ref11">11</xref>
                    </sup> The SP5 was fitted with the following lasers: Argon, 546, 633 and a tunable infrared multiphoton laser (Spectraphysics Mai Tai 690-1020). The Zeiss LSM 780 was fitted with the following lasers: Argon, 561, 633 and a tuneable infrared multiphoton laser (Spectraphysics Mai Tai DeepSee 690-1040). The signal was visualized with a Leica HCX IRAPO L &#x00d7;25 water immersion lens (0.95 N.A) and a W Plan-Apochromat &#x00d7;20 DIC water immersion lens (1.0 N.A), respectively. Collagen bone second harmonic generation signal and GFP and CFP signals were generated through excitation at 840 and 870 nm and detected with external detectors. Internal detectors were used to collect DsRed and Cy5 signals (and on some occasions, GFP). Anaesthesia was induced in mice with 4% isoflurane mixed with pure oxygen. This was gradually reduced to approximately 1% as anaesthesia stabilised. Animals were randomly assigned to each group (na&#x00ef;ve control, propofol treated, and sevoflurane treated).</p>
                <p>Surgery to attach the headpiece was then performed as described below.
                    <list list-type="order">
                        <list-item>
                            <label>1)</label>
                            <p>Sterile forceps and scissors were used to carefully remove the central portion of the scalp to expose the calvarium area to be imaged. Then, a small incision was made at the back of the head between the ears by lifting the skin up with the forceps. While holding the skin up, scissors were slid under the skin and gently cut along the outside of the desired imaging area.</p>
                        </list-item>
                        <list-item>
                            <label>2)</label>
                            <p>An adequate amount of dental cement was mixed in a weigh boat until it became a paste and it was quickly applied to the bottom surface of the headpiece that will attach to the skull.</p>
                        </list-item>
                        <list-item>
                            <label>3)</label>
                            <p>Before the cement set, headpiece was placed onto the skull of the mouse, making sure not to get any dental cement on the imaging area. Then, it was important to wait for it to set.</p>
                        </list-item>
                        <list-item>
                            <label>4)</label>
                            <p>The headpiece was attached to the holder and secured in place using the screw, ensuring that the grooves fit within the holder notches.</p>
                        </list-item>
                    </list>
                </p>
                <p>Large three-dimensional &#x2018;tile scans&#x2019; of the entire BM cavity space were acquired by stitching adjacent, high-resolution z-stack images using a surgically implanted imaging window that ensures steady positioning of mice on the microscope. Time-lapse datasets were acquired by focusing on one area of BM. One image was taken every three minutes for a total of 22 images. Then, all 22 images were combined together to produce a movie (time-lapse). The calvarium has been demonstrated to be equivalent to the long bones such as the femur with regards to haematopoietic stem cell frequency, function, and localization, and is the only BM compartment that allows longitudinal imaging through minimally invasive surgery. Blood vessels were highlighted by I.V. injection of 50 &#x03bc;l of 8 mg/ml 500 kDa Cy5-Dextran (Nanocs, MA). After the intravital microscopy, all mice were euthanised 
                    <italic toggle="yes">via</italic> cervical dislocation.</p>
            </sec>
            <sec id="sec12">
                <title>Image quantification</title>
                <p>Microscopy data was processed using multiple platforms. Tile scans were stitched using ZEN black, RRID:SCR_018163 (Zeiss, Germany) software. Raw data were visualised and processed using Fiji/Image J, RRID:SCR_00285 (National Institutes of Health, Maryland, USA). Cell tracking was performed using FIJI plugin MTrackJ. For accuracy in cell tracking data, videos were registered when required before using four-dimensional data protocols implemented in Fiji. Three-dimensional data rendering and measurement of cell distances were performed in Volocity, RRID:SCR_002668 (Perkin Elmer, MA, USA).</p>
            </sec>
            <sec id="sec13">
                <title>Statistical analysis</title>
                <p>The sample size required for the experiments was estimated based on the results of preliminary data. Statistical differences between the means of two data groups were determined using two-tailed unpaired Student&#x2019;s t-test, and p values&lt;0.05 were considered statistically significant. Multiple group comparisons were performed using ANOVA with a Kruskal-Wallis nonparametric or Bonferroni&#x2019;s 
                    <italic toggle="yes">post hoc</italic> test for comparisons GraphPad Prism 7.0, RRID:SCR_002798. A p value&lt;0.05 was considered statistically significant.</p>
            </sec>
        </sec>
        <sec id="sec14" sec-type="results">
            <title>Results</title>
            <sec id="sec15">
                <title>General anaesthetics reduce the migration of leukaemia cells 
                    <italic toggle="yes">in vitro</italic> and 
                    <italic toggle="yes">in vivo</italic>
                </title>
                <p>Before assessing their effects on cell migration, cell toxicity of propofol and sevoflurane were assessed 
                    <italic toggle="yes">via</italic> propidium iodide staining. No cell death was detected in NLAM-6 and Reh cells after exposure to propofol and sevoflurane (
                    <xref ref-type="fig" rid="f1">Figure 1a</xref>-
                    <xref ref-type="fig" rid="f1">c</xref>).</p>
                <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                    <label>Figure 1. </label>
                    <caption>
                        <title>General anaesthetics do not affect cell 
                            <italic toggle="yes">via</italic>bility of NALM-6 cells.</title>
                        <p>a-b) NALM-6 cells were treated with intralipid, 10 &#x03bc;g/ml propofol and 3.6% sevoflurane for six hours. Cell 
                            <italic toggle="yes">via</italic>bility was detected using through flow cytometry by propidium iodide-based assay. Data are illustrated as mean&#x00b1;sd (n=4). NC: Na&#x00ef;ve control. VC: Vehicle control (Intralipid). c) NALM-6 cells were treated with 10 &#x03bc;g/ml propofol and 3.6% sevoflurane for six hours. Cell 
                            <italic toggle="yes">via</italic>bility was detected through flow cytometry by propidium iodide-based assay. Images shown here are representative images selected from 4 repeats.</p>
                    </caption>
                    <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/138230/fe0f8bdf-cfc2-4464-914d-b8fd2ba743eb_figure1.gif"/>
                </fig>
                <p>We investigated whether the migration of leukaemia cells was affected by general anaesthetics. An 
                    <italic toggle="yes">in vitro</italic> migration chamber was set up where 2 &#x00d7; 10
                    <sup>5</sup> of NLAM-6 (pre-treated with propofol or sevoflurane for six hours) were loaded into the upper chamber and allowed to migrate for six hours to the lower chamber where 1 nM of SDF-1, a CXCR4 ligand, was applied. We observed that 10 &#x03bc;g/ml (56 &#x03bc;M) of propofol led to a significant reduction in the number of cells migrating to the lower chamber (almost a 50% decrease) (
                    <xref ref-type="fig" rid="f2">Figure 2a</xref>). Similarly, sevoflurane, on average, reduced cell migration to the lower chamber by approximately 35%, compared with na&#x00ef;ve control (
                    <xref ref-type="fig" rid="f2">Figure 2a</xref>). Intralipid (vehicle control) had no effect on cell migration.</p>
                <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                    <label>Figure 2. </label>
                    <caption>
                        <title>General anaesthetics reduce cell migration 
                            <italic toggle="yes">in vitro</italic> and 
                            <italic toggle="yes">in vivo.</italic>
                        </title>
                        <p>a) NALM-6 cells were initially treated with intralipid (VC), 10 &#x03bc;g/ml propofol and 3.6% sevoflurane for six hours. Then, treated cells were loaded into the migration chamber with 1 nM SDF-1 in the lower chamber as the chemoattractant. Cells were allowed to pass through migration chambers for six hours. Cells in the lower chamber were collected and counted in a flow cytometer. Data are shown as mean&#x00b1;sd (n=4). For propofol statistics, *p&lt;0.05 vs na&#x00ef;ve control (NC). ##p&lt;0.01 vs vehicle control (VC). Data are analysed by one-way ANOVA followed by Bonferroni&#x2019;s 
                            <italic toggle="yes">post hoc</italic> test. For sevoflurane statistics, *p&lt;0.05 vs na&#x00ef;ve control (NC). Data are analysed by unpaired t-test. NC: na&#x00ef;ve control, VC: intralipid, P10: 10 &#x03bc;g/ml propofol, and Sevo: 3.6% sevoflurane. b) Intravital confocal calvarium imaging of GFP-transduced NLAM-6 cells (red) was performed after injection of GFP-NALM-6 cells into C57BL/6 mice IV. GFP-NALM-6 cells were pre-treated with either 10 &#x03bc;g/ml of propofol or 3.6% sevoflurane overnight 
                            <italic toggle="yes">in vitro</italic> prior to injections. Respective time-lapses were shown following IV injection of tritc-dextran to identify blood vessels (green); non leukaemia cells with high autofluorescent signals (blue) were recorded as well to improve the identification of target cells. Scale bar: 50 &#x03bc;m. Each position was imaged at three-minute intervals for 66 minutes. We only investigated the migration of cells in bone marrow. Cells in blood vessels were excluded from our investigations. Top row: Mouse injected with untreated cells (red). NC: na&#x00ef;ve control. Middle row: Cells were pre-treated with 10 &#x03bc;g/ml of propofol overnight 
                            <italic toggle="yes">in vitro</italic> prior to injection. Bottom row: Cells were pre-treated with 3.6% of sevoflurane prior to injection. Displacement of each cell captured in all time-lapses was recorded. Data are pooled from 3 na&#x00ef;ve control mice (N=3, 113 cells), 4 mice injected with propofol treated cells (n=4, 86 cells) and 4 mice injected with sevoflurane treated cells (N=4, 88 cells). Data are illustrated as mean&#x00b1;sd. For displacement data, *p&lt;0.05, ***p&lt;0.001, vs na&#x00ef;ve control (NC). Data are analysed by one-way non-parametric ANOVA test (Kruskal-Wallis test). Propofol: 10 &#x03bc;g/ml of propofol and Sevoflurane: 3.6% of sevoflurane.</p>
                        <p>Mean speed of each cell captured in time-lapses was recorded. Data is pooled from 3 na&#x00ef;ve control mice (N=3, 113 cells), 4 propofol pre-treated mice (N=4, 86 cells) and 4 sevoflurane treated mice (N=4, 88 cells). Data are illustrated as mean&#x00b1;sd. *p&lt;0.05, **p&lt;0.01, vs na&#x00ef;ve control (NC). Data is analysed by one-way non-parametric ANOVA test (Kruskal-Wallis test). Propofol: cells were pre-treated with 10 &#x03bc;g/ml of propofol for six hours and Sevoflurane: cells were pre-treated with 3.6% of sevoflurane for six hours.</p>
                    </caption>
                    <graphic id="gr2" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/138230/fe0f8bdf-cfc2-4464-914d-b8fd2ba743eb_figure2.gif"/>
                </fig>
                <p>In order to validate our 
                    <italic toggle="yes">in vitro</italic> migration results, we set up a mouse model to study migration using intravital microscopy.
                    <sup>
                        <xref ref-type="bibr" rid="ref12">12</xref>
                    </sup> In our model, we used immune-competent C57BL-6 mice instead of SCID mice for homing and migration experiments as it is a well-established model for non-maintenance cancer studies.
                    <sup>
                        <xref ref-type="bibr" rid="ref13">13</xref>
                    </sup> GFP-NALM-6 cells (pre-treated with 10 &#x03bc;g/ml propofol or 3.6% sevoflurane for six hours) were injected intravenously. Then, intravital microscopy was performed. Only cells present in all time lapse images were tracked and included in our displacement analysis. In addition, cells inside blood vessels were not included in analysis. Displacements were calculated by adding all displacements in each time interval. The mean speed was calculated by averaging all mean speed recorded in each time interval. Our results showed that general anaesthetic pre-treated cells appeared to achieve smaller displacements compared to na&#x00ef;ve cells, and their mean migration speed was also significantly reduced (
                    <xref ref-type="fig" rid="f2">Figure 2b</xref>). It was very obvious that after propofol and sevoflurane exposure, the number of fast-moving cells was significantly reduced (
                    <xref ref-type="fig" rid="f2">Figure 2b</xref>).</p>
            </sec>
            <sec id="sec16">
                <title>General anaesthetics reduce the homing of NALM-6 cells 
                    <italic toggle="yes">in vivo</italic>
                </title>
                <p>After revealing that cell migration was reduced by general anaesthetics, we investigated whether the homing process was affected by anaesthetics specifically in terms of 1) homing location of cells (expressed by the distance between each cell to the nearest endosteal surface); 2) The number of cells entering bone marrow. Tile scan imaging (
                    <xref ref-type="fig" rid="f3">Figure 3a</xref>) of large areas of mouse calvarium bone marrow was carried out and the distance between each cell and the nearest endosteal bone surface was calculated. We used this distance as an indication for homing location. Cells in the blood vessels were not included in our analysis. Results showed that the average distance between a leukaemia cell and the endosteal bone surface was increased by propofol and sevoflurane, indicating disruption of the homing process (
                    <xref ref-type="fig" rid="f3">Figure 3b</xref>). Na&#x00ef;ve control cells consistently move to locations approximately within 100 &#x03bc;m of the endosteal surface in bone marrow (
                    <xref ref-type="fig" rid="f3">Figure 3b</xref>). Presumably, this is a discrete region near vessels demonstrated previously,
                    <sup>
                        <xref ref-type="bibr" rid="ref8">8</xref>
                    </sup> though the previous publication did not measure the distance between cells and the endosteal bone surface. After exposure to propofol or sevoflurane, a fair proportion of cells was found in locations further away from the endosteal bone surface (
                    <xref ref-type="fig" rid="f3">Figure 3b</xref>).</p>
                <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                    <label>Figure 3. </label>
                    <caption>
                        <title>General anaesthetics affect the homing of ALL cells entering bone marrow and affect the homing location of ALL cells 
                            <italic toggle="yes">in vivo.</italic>
                        </title>
                        <p>a) Upper left: diagram showing strategy for calvarium imaging.</p>
                        <p>Intravital confocal calvarium imaging of GFP-transduced NLAM-6 cells (red) was performed after injection of GFP-NALM-6 cells into C57BL/6 mice IV. GFP-NALM-6 cells were pre-treated with either 10 &#x03bc;g/ml of propofol or 3.6% of sevoflurane prior to injection. Representative maximum projection tile scans and corresponding high-magnification inserts were shown following IV injection of tritc-dextran to identify blood vessels (green); non leukaemia cells with high autofluorescent signals (green, spotty signal) were recorded as well to improve the identification of target cells. Higher magnification images show portions of low magnification tile scans. Scale bar: 500 &#x03bc;m for low magnification tile scan. 50 &#x03bc;m for high magnification images. b) The distance between the nearest bone surface (not shown) and each GFP-NALM-6 cell was measured. Data illustrated as mean&#x00b1;sd. Data are pooled from 4 na&#x00ef;ve control mice (N=4, 279 cells), 4 mice injected with propofol treated cells (n=4, 134 cells) and 6 mice injected with sevoflurane treated cells (n=6, 366 cells). *p&lt;0.05 vs na&#x00ef;ve control (NC). Data are analysed by one-way non-parametric ANOVA test (Kruskal-Wallis test). c) We calculated the number of cells enter bone marrow space from IVM images for each treatment group. Data are illustrated as mean&#x00b1;sd. Data are pooled from nine na&#x00ef;ve control mice, eight mice injected with propofol pre-treated cells and six mice injected with sevoflurane pre-treated cells. *p&lt;0.05 vs na&#x00ef;ve control (NC). Data are analysed by one-way non-parametric ANOVA test (Kruskal-Wallis test). Propofol: cells were pre-treated with 10 &#x03bc;g/ml of propofol for six hours, Sevoflurane: cells were pre-treated with 3.6% of sevoflurane for six hours.</p>
                    </caption>
                    <graphic id="gr3" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/138230/fe0f8bdf-cfc2-4464-914d-b8fd2ba743eb_figure3.gif"/>
                </fig>
                <p>We then studied whether treatment with general anaesthetics affected the number of cells entering bone marrow by counting the number of GFP+ cells from tile scans. Our results demonstrated that treatment with propofol and sevoflurane caused a significant reduction in the number of NALM-6-GFP cells entering bone marrow (
                    <xref ref-type="fig" rid="f3">Figure 3c</xref>). After either treatment, fewer than 100 GFP-NLAM-6 cells entered the bone marrow compared to an average of nearly 200 cells entering the bone marrow for na&#x00ef;ve control cells.</p>
            </sec>
            <sec id="sec17">
                <title>General anaesthetics reduce the leukaemia cell surface CXCR4 expression and reduce the adhesion of leukaemia cells to thrombin-cleaved OPN 
                    <italic toggle="yes">in vitro</italic>
                </title>
                <p>CXCR4 is crucial for migration
                    <sup>
                        <xref ref-type="bibr" rid="ref14">14</xref>
                    </sup> and homing
                    <sup>
                        <xref ref-type="bibr" rid="ref8">8</xref>
                    </sup> of leukaemia cells in the bone marrow. One study demonstrated that B-ALL cells (NALM-6 cells) home to discreet, discontinuous locations near vessels in bone marrow that express the adhesion molecules E-selectin and SDF-1.
                    <sup>
                        <xref ref-type="bibr" rid="ref8">8</xref>
                    </sup> Disruption of the interactions of the SDF-1-CXCR4 axis inhibited the homing of GFP-NALM-6 cells to these vessels.
                    <sup>
                        <xref ref-type="bibr" rid="ref8">8</xref>
                    </sup> We hypothesised that CXCR4 was one of the key factors in general anaesthetics-mediated reduction of the migration and homing of GFP-NALM-6 cells 
                    <italic toggle="yes">in vivo.</italic> In order to validate this, we treated NALM-6 cells with propofol (5 and 10 &#x03bc;g/ml) and sevoflurane (3.6% MAC 2) followed by flow cytometry analysis of surface CXCR4 expression. Our results indicated that both propofol and sevoflurane significantly reduced surface CXCR4 expression (
                    <xref ref-type="fig" rid="f4">Figure 4a</xref>). More specifically, 5 and 10 &#x03bc;g/ml of propofol (28 and 56 &#x03bc;M) reduced CXCR4 expression in a dose-dependent manner (
                    <xref ref-type="fig" rid="f4">Figure 4a</xref>). Only six hours of sevoflurane significantly reduced CXCR4 (
                    <xref ref-type="fig" rid="f4">Figure 4a</xref>). These results suggest that CXCR4 might be the key behind general anaesthetics-mediated reduction of homing and migration in leukaemia cells.</p>
                <fig fig-type="figure" id="f4" orientation="portrait" position="float">
                    <label>Figure 4. </label>
                    <caption>
                        <title>General anaesthetics reduce cell surface CXCR4 and 
                            <italic toggle="yes">in vitro</italic> adhesion to thrombin-cleaved osteopontin.</title>
                        <p>a) NALM-6 cells were treated by intralipid (VC), 5 &#x03bc;g/ml and 10 &#x03bc;g/ml of propofol for six hours. Or cells were treated by 3.6% of sevoflurane for two, four, and six hours. Following the general anaesthetics treatment, treated cells were stained with a CXCR4 antibody and analysed by flow cytometer for mean fluorescence intensity. Data are illustrated as mean&#x00b1;sd (N=4). Data are analysed by one-way ANOVA followed by Bonferroni&#x2019;s 
                            <italic toggle="yes">post hoc</italic> test. For propofol statistics, *p&lt;0.05, **p&lt;0.01, vs na&#x00ef;ve control (NC). #p&lt;0.05 vs vehicle control (VC). For sevoflurane statistics, *p&lt;0.05. VC: intralipid, P5: 5 &#x03bc;g/ml of propofol, P10: 10 &#x03bc;g/ml of propofol, Sevo 2: two hours sevoflurane, Sevo 4: four hours sevoflurane and Sevo 6: six hours sevoflurane. b) NALM-6 cells were either untreated or treated with 3.6% sevoflurane for six hours initially. Then they were allowed to adhere to plates pre-coated with thrombin cleaved osteopontin for two hours. Data are illustrated as mean&#x00b1;sd (N=4). *p&lt;0.05 vs thrombin-cleaved OPN. Data are analysed by one-way ANOVA followed by Bonferroni&#x2019;s 
                            <italic toggle="yes">post hoc</italic> test. 
                            <bold>c)</bold> NALM-6 cells were either untreated or treated with 10 &#x03bc;g/ml of propofol for six hours initially. Then they were allowed to adhere to plates pre-coated with thrombin-cleaved osteopontin for two hours. Data are illustrated as mean&#x00b1;sd (N=4). *p&lt;0.05. Data are analysed by one-way ANOVA followed by Bonferroni&#x2019;s 
                            <italic toggle="yes">post hoc</italic> test. LIPID: intralipid.</p>
                    </caption>
                    <graphic id="gr4" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/138230/fe0f8bdf-cfc2-4464-914d-b8fd2ba743eb_figure4.gif"/>
                </fig>
                <p>In addition to CXCR4, we then speculated that the changes in the number and position of GFP-NALM-6 cells homed to the BM was due to the disruption of interactions between leukaemia cells and components of bone marrow matrix. We firstly investigated the expression of integrin &#x03b1;4 (CD49d), which is one of the dimers of &#x03b1;4&#x03b2;1 integrin or very late antigen 4 (VLA-4) (the other one being integrin &#x03b2;1), after exposure to general anaesthetics. VLA-4 is an essential mediator for engraftment of NALM-6 cells in bone marrow by anchoring NALM-6 cells to bone marrow matrix and supporting leukaemia growth.
                    <sup>
                        <xref ref-type="bibr" rid="ref10">10</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref15">15</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref16">16</xref>
                    </sup> The prime target for VLA-4 adhesion is osteopontin (OPN). Interestingly, no significant change was detected in the expression of the &#x03b1;4 subunit after anaesthetics exposure (Supplementary figure 1a and b). Next, we hypothesised that general anaesthetics might affect the adhesion of NALM-6 cells to OPN. Given that OPN has various isoforms in bone marrow, we tested the adhesion of leukaemia cells to thrombin-cleaved OPN, which is the most dominant form of OPN in bone marrow.
                    <sup>
                        <xref ref-type="bibr" rid="ref9">9</xref>
                    </sup> Similar to a previous study,
                    <sup>
                        <xref ref-type="bibr" rid="ref10">10</xref>
                    </sup> NALM-6 cells only weakly adhered to full-length OPN but they showed strong adhesion to thrombin-cleaved OPN (Supplementary figure 1c). Consistent with our hypothesis, when cells were pre-treated with propofol and sevoflurane, the percentage of cells adhered to thrombin-cleaved OPN was significantly reduced (
                    <xref ref-type="fig" rid="f4">Figure 4b</xref> and 
                    <xref ref-type="fig" rid="f4">c</xref>).</p>
            </sec>
        </sec>
        <sec id="sec18" sec-type="discussion">
            <title>Discussion</title>
            <p>Our work, for the first time, demonstrates that general anaesthetics reduce the migration and homing of ALL cells 
                <italic toggle="yes">via</italic> CXCR4 and OPN mediated mechanisms. By using 
                <italic toggle="yes">in vitro</italic> models and an immunocompetent mouse model, we found that both propofol and sevoflurane lead to a reduction in CXCR4 expression and disruption of adhesion to thrombin-cleaved osteopontin in leukaemia cells. These effects were associated with reprogramming of the bone marrow microenvironment to unfavourable conditions for leukaemia cells, as illustrated in the reduction of migration speed, the disruption of homing locations, and the reduction in the number of cells entering bone marrow.</p>
            <p>The importance of CXCR4 (specifically the SDF-1-CXCR4 axis) in B-ALL homing and migration has been well documented.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref14">14</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref17">17</xref>
                </sup> Our CXCR4 expression data is novel and provides direct evidence for the effect of anaesthetics on migration, demonstrating that general anaesthetics reduce CXCR4-dependent chemotaxis in NALM-6 cells.</p>
            <p>Homing is a vital process in the early stages of leukaemia development. It allows leukaemia cells to seed, multiply, and importantly, evade detection by the immune system. B-ALL cells have been demonstrated to home to unique anatomic regions in bone marrow.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup> It was reasonable to assume that the suppression of CXCR4 by general anaesthetics was one of the reasons for the disruption of homing in our study. Our 
                <italic toggle="yes">in vitro</italic> data also showed that the adhesion of ALL to thrombin-cleaved osteopontin is reduced by propofol and sevoflurane. Thrombin-cleaved osteopontin is a prominent adhesion molecule in bone marrow, which regulates the binding of leukaemia to bone marrow niches required for homing. The mechanism behind the reduction in adhesion caused by general anaesthetics is not known as VLA-4 receptor expression is not affected by general anaesthetic exposure. In addition to homing disturbance, we found that the number of leukaemia cells entering the bone marrow space was reduced by general anaesthetic treatment 
                <italic toggle="yes">in vivo.</italic> This may possibly be due to the reduction of surface CXCR4 on NALM-6 cells caused by general anaesthetics. </p>
            <p>Looking at clinical studies, a few retrospective studies and one meta-analysis have investigated the beneficial effect of general anaesthetics on cancer outcomes, and propofol may be associated with improved recurrence-free survival and overall survival in patients having cancer surgery.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref18">18</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref22">22</xref>
                </sup> Further clinical studies, including whether propofol is beneficial for ALL patients, are urgently needed. Ideally, anaesthetics without any effects on cancer cell malignancy or, even better, with some potential anti-cancer properties should be chosen to use in cancer patients during surgery. Ultimately, cancer patients will get enormous benefits from such changes in clinical practice and very importantly, such changes will not incur significant cost on the healthcare system.</p>
            <p>Our study is not without limitations. Firstly, leukaemia cells were pre-treated with propofol or sevoflurane before injection in 
                <italic toggle="yes">in vivo</italic> models, which eliminates the complexities of drug metabolism 
                <italic toggle="yes">in vivo.</italic> For further studies, it would be interesting to treat mice with propofol and sevoflurane directly. In addition, long-term studies could be established in which propofol and sevoflurane are given to leukaemia-bearing mice with established disease to mimic real clinical scenarios.</p>
            <p>Secondly, the concentration of anaesthetics used for our study may be more applicable to paediatric patients. Clinical doses of general anaesthetics for invasive procedures in adult patients are generally lower and shorter in duration for such procedures. However, the clinical doses of general anaesthetics in paediatric patients are relatively high; for example, the use of 3.6% or higher concentrations of sevoflurane for paediatric leukaemia treatment procedures is well documented.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref23">23</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref25">25</xref>
                </sup> Additionally, the plasma concentration of propofol was reported to be high in paediatric procedures (plasma concentration range between 6 &#x03bc;g/ml to 2 &#x03bc;g/ml).
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup> Furthermore, these patients are subject to frequent exposure to general anaesthetics. Therefore, the cumulative dose of anaesthetic exposure for this group of patients is considerably high.</p>
        </sec>
        <sec id="sec19" sec-type="conclusion">
            <title>Conclusion</title>
            <p>In the present study, we investigated the effect of two commonly used general anaesthetics, propofol and sevoflurane, on ALL cell migration and homing exemplified by 1) the number of cells entering bone marrow and 2) the homing location in relation to the nearest endosteal surface. Our data suggest that both general anaesthetics reduced the homing and migration of ALL cells 
                <italic toggle="yes">in vitro</italic> and 
                <italic toggle="yes">in vivo.</italic> Our results indicated that general anaesthetics reduced the surface CXCR4 expression. In addition, the adhesion of leukaemia cells to thrombin cleaved osteopontin (OPN) was reduced by general anaesthetics.</p>
            <p>We focussed on changes driven by ex vivo exposure to propofol and sevoflurane, however it is possible that these drugs might also re-program the bone marrow to be a more hostile environment for ALL cells and thus, in turn reduce the overall malignancy of ALL. Therefore, both anaesthetics may be safely used in patients undergoing procedures during ALL treatments but this warrants further clinical studies.</p>
        </sec>
        <sec id="sec20">
            <title>Ethics</title>
            <p>All procedures performed relating to animal experiments in this study were approved by the Animal Welfare and Ethical Review Body (AWERB), Imperial College London and the Home Office, United Kingdom with PPL number 70/8496.</p>
        </sec>
        <sec id="sec21">
            <title>Authors&#x2019; contributions</title>
            <p>J.C., D.Q.M. and C.L.C. conceived the project. C.L.C. developed the intravital microscopy (IVM) method. J.C. performed all experiments, data analysis and wrote the manuscript. S.G.A. and X.M.L. helped perform the IVM experiment and helped IVM data analysis. All authors read and approved the final submission.</p>
        </sec>
    </body>
    <back>
        <sec id="sec22" sec-type="data-availability">
            <title>Data availability</title>
            <sec id="sec23">
                <title>Underlying data</title>
                <p>Zendo: General anaesthetics reduce acute lymphoblastic leukaemia cell migration and homing 
                    <italic toggle="yes">in vitro</italic> and 
                    <italic toggle="yes">in vivo via</italic> CXCR4 and osteopontin mediated mechanisms, 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7261294">https://doi.org/10.5281/zenodo.7261294</ext-link>.
                    <sup>

                        <xref ref-type="bibr" rid="ref26">26</xref>
</sup>
                </p>
                <p>This project contains following underlying data:
                    <list list-type="bullet">
                        <list-item>
                            <label>-</label>
                            <p>Author Checklist - Full.pdf</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>Cell adhesion assay.xlsx</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>Flow data.xlsx</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>IVM data.xlsx</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>Nc cells.avi</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>propofol cells.avi</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>sevoflurane cells.avi</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>sub Figures F1000 JC.dox</p>
                        </list-item>
                    </list>
                </p>
                <p>Data are available under the terms of the 
                    <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link> (CC-BY 4.0).</p>
            </sec>
        </sec>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hunger</surname>
                            <given-names>SP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mullighan</surname>
                            <given-names>CG</given-names>
                        </name>
</person-group>:
                    <article-title>Acute Lymphoblastic Leukemia in Children.</article-title>
                    <source>

                        <italic toggle="yes">N. Engl. J. Med.</italic>
</source>
                    <year>2015</year>;<volume>373</volume>(<issue>16</issue>):<fpage>1541</fpage>&#x2013;<lpage>1552</lpage>.
                    <pub-id pub-id-type="doi">10.1056/NEJMra1400972</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Percival</surname>
                            <given-names>ME</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lai</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Estey</surname>
                            <given-names>E</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.</article-title>
                    <source>

                        <italic toggle="yes">Blood Rev.</italic>
</source>
                    <year>2017</year>;<volume>31</volume>(<issue>4</issue>):<fpage>185</fpage>&#x2013;<lpage>192</lpage>.
                    <pub-id pub-id-type="pmid">28190619</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.blre.2017.01.003</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Gaynor</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ansermino</surname>
                            <given-names>JM</given-names>
                        </name>
</person-group>:
                    <article-title>Paediatric total intravenous anaesthesia.</article-title>
                    <source>

                        <italic toggle="yes">BJA Education.</italic>
</source>
                    <year>2016</year>;<volume>16</volume>(<issue>11</issue>):<fpage>369</fpage>&#x2013;<lpage>373</lpage>.
                    <pub-id pub-id-type="doi">10.1093/bjaed/mkw019</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ma</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lim</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Xu</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Xenon preconditioning protects against renal ischemic-reperfusion injury 
                        <italic toggle="yes">via</italic> HIF-1alpha activation.</article-title>
                    <source>

                        <italic toggle="yes">J. Am. Soc. Nephrol.</italic>
</source>
                    <year>2009</year>;<volume>20</volume>(<issue>4</issue>):<fpage>713</fpage>&#x2013;<lpage>720</lpage>.
                    <pub-id pub-id-type="pmid">19144758</pub-id>
                    <pub-id pub-id-type="doi">10.1681/ASN.2008070712</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Huang</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Benzonana</surname>
                            <given-names>LL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhao</surname>
                            <given-names>H</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Prostate cancer cell malignancy 
                        <italic toggle="yes">via</italic> modulation of HIF-1alpha pathway with isoflurane and propofol alone and in combination.</article-title>
                    <source>

                        <italic toggle="yes">Br. J. Cancer.</italic>
</source>
                    <year>2014</year>;<volume>111</volume>(<issue>7</issue>):<fpage>1338</fpage>&#x2013;<lpage>1349</lpage>.
                    <pub-id pub-id-type="pmid">25072260</pub-id>
                    <pub-id pub-id-type="doi">10.1038/bjc.2014.426</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Benzonana</surname>
                            <given-names>LL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Perry</surname>
                            <given-names>NJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Watts</surname>
                            <given-names>HR</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential 
                        <italic toggle="yes">via</italic> the hypoxia-inducible factor cellular signaling pathway 
                        <italic toggle="yes">in vitro.</italic>
</article-title>
                    <source>

                        <italic toggle="yes">Anesthesiology.</italic>
</source>
                    <year>2013</year>;<volume>119</volume>(<issue>3</issue>):<fpage>593</fpage>&#x2013;<lpage>605</lpage>.
                    <pub-id pub-id-type="pmid">23774231</pub-id>
                    <pub-id pub-id-type="doi">10.1097/ALN.0b013e31829e47fd</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wigmore</surname>
                            <given-names>TJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mohammed</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jhanji</surname>
                            <given-names>S</given-names>
                        </name>
</person-group>:
                    <article-title>Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery: A Retrospective Analysis.</article-title>
                    <source>

                        <italic toggle="yes">Anesthesiology.</italic>
</source>
                    <year>2016</year>;<volume>124</volume>(<issue>1</issue>):<fpage>69</fpage>&#x2013;<lpage>79</lpage>.
                    <pub-id pub-id-type="doi">10.1097/ALN.0000000000000936</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Sipkins</surname>
                            <given-names>DA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wei</surname>
                            <given-names>X</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wu</surname>
                            <given-names>JW</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment.</article-title>
                    <source>

                        <italic toggle="yes">Nature.</italic>
</source>
                    <year>2005</year>;<volume>435</volume>(<issue>7044</issue>):<fpage>969</fpage>&#x2013;<lpage>973</lpage>.
                    <pub-id pub-id-type="pmid">15959517</pub-id>
                    <pub-id pub-id-type="doi">10.1038/nature03703</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <label>9</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Grassinger</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Haylock</surname>
                            <given-names>DN</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Storan</surname>
                            <given-names>MJ</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins.</article-title>
                    <source>

                        <italic toggle="yes">Blood.</italic>
</source>
                    <year>2009</year>;<volume>114</volume>(<issue>1</issue>):<fpage>49</fpage>&#x2013;<lpage>59</lpage>.
                    <pub-id pub-id-type="pmid">19417209</pub-id>
                    <pub-id pub-id-type="doi">10.1182/blood-2009-01-197988</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <label>10</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Boyerinas</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zafrir</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yesilkanal</surname>
                            <given-names>AE</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy.</article-title>
                    <source>

                        <italic toggle="yes">Blood.</italic>
</source>
                    <year>2013</year>;<volume>121</volume>(<issue>24</issue>):<fpage>4821</fpage>&#x2013;<lpage>4831</lpage>.
                    <pub-id pub-id-type="pmid">23589674</pub-id>
                    <pub-id pub-id-type="doi">10.1182/blood-2012-12-475483</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <label>11</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Lo Celso</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fleming</surname>
                            <given-names>HE</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wu</surname>
                            <given-names>JW</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche.</article-title>
                    <source>

                        <italic toggle="yes">Nature.</italic>
</source>
                    <year>2009</year>;<volume>457</volume>(<issue>7225</issue>):<fpage>92</fpage>&#x2013;<lpage>96</lpage>.
                    <pub-id pub-id-type="pmid">19052546</pub-id>
                    <pub-id pub-id-type="doi">10.1038/nature07434</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref12">
                <label>12</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hawkins</surname>
                            <given-names>ED</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Duarte</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Akinduro</surname>
                            <given-names>O</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments.</article-title>
                    <source>

                        <italic toggle="yes">Nature.</italic>
</source>
                    <year>2016</year>;<volume>538</volume>(<issue>7626</issue>):<fpage>518</fpage>&#x2013;<lpage>522</lpage>.
                    <pub-id pub-id-type="pmid">27750279</pub-id>
                    <pub-id pub-id-type="doi">10.1038/nature19801</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref13">
                <label>13</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>SH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Park</surname>
                            <given-names>SA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zou</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Real-Time Monitoring of Cancer Cells in Live Mouse Bone Marrow.</article-title>
                    <source>

                        <italic toggle="yes">Front. Immunol.</italic>
</source>
                    <year>2018</year>;<volume>9</volume>.
                    <pub-id pub-id-type="pmid">30116236</pub-id>
                    <pub-id pub-id-type="doi">10.3389/fimmu.2018.01681</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref14">
                <label>14</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Spiegel</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kollet</surname>
                            <given-names>O</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Peled</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling.</article-title>
                    <source>

                        <italic toggle="yes">Blood.</italic>
</source>
                    <year>2004</year>;<volume>103</volume>(<issue>8</issue>):<fpage>2900</fpage>&#x2013;<lpage>2907</lpage>.
                    <pub-id pub-id-type="pmid">15070661</pub-id>
                    <pub-id pub-id-type="doi">10.1182/blood-2003-06-1891</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref15">
                <label>15</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Filshie</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gottlieb</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bradstock</surname>
                            <given-names>K</given-names>
                        </name>
</person-group>:
                    <article-title>VLA-4 is involved in the engraftment of the human pre-B acute lymphoblastic leukaemia cell line NALM-6 in SCID mice.</article-title>
                    <source>

                        <italic toggle="yes">Br. J. Haematol.</italic>
</source>
                    <year>1998</year>;<volume>102</volume>(<issue>5</issue>):<fpage>1292</fpage>&#x2013;<lpage>1300</lpage>.
                    <pub-id pub-id-type="pmid">9753059</pub-id>
                    <pub-id pub-id-type="doi">10.1046/j.1365-2141.1998.00899.x</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref16">
                <label>16</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ryan</surname>
                            <given-names>DH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nuccie</surname>
                            <given-names>BL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Abboud</surname>
                            <given-names>CN</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Invest.</italic>
</source>
                    <year>1991</year>;<volume>88</volume>(<issue>3</issue>):<fpage>995</fpage>&#x2013;<lpage>1004</lpage>.
                    <pub-id pub-id-type="pmid">1715889</pub-id>
                    <pub-id pub-id-type="doi">10.1172/JCI115403</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref17">
                <label>17</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Shen</surname>
                            <given-names>W</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bendall</surname>
                            <given-names>LJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gottlieb</surname>
                            <given-names>DJ</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>The chemokine receptor CXCR4 enhances integrin-mediated 
                        <italic toggle="yes">in vitro</italic> adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow.</article-title>
                    <source>

                        <italic toggle="yes">Exp. Hematol.</italic>
</source>
                    <year>2001</year>;<volume>29</volume>(<issue>12</issue>):<fpage>1439</fpage>&#x2013;<lpage>1447</lpage>.
                    <pub-id pub-id-type="pmid">11750103</pub-id>
                    <pub-id pub-id-type="doi">10.1016/S0301-472X(01)00741-X</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref18">
                <label>18</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yoo</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>HB</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Han</surname>
                            <given-names>W</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Total Intravenous Anesthesia versus Inhalation Anesthesia for Breast Cancer Surgery: A Retrospective Cohort Study.</article-title>
                    <source>

                        <italic toggle="yes">Anesthesiology.</italic>
</source>
                    <year>2019</year>;<volume>130</volume>(<issue>1</issue>):<fpage>31</fpage>&#x2013;<lpage>40</lpage>.
                    <pub-id pub-id-type="doi">10.1097/ALN.0000000000002491</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref19">
                <label>19</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zheng</surname>
                            <given-names>X</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wang</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dong</surname>
                            <given-names>L</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Effects of propofol-based total intravenous anesthesia on gastric cancer: a retrospective study.</article-title>
                    <source>

                        <italic toggle="yes">Onco. Targets. Ther.</italic>
</source>
                    <year>2018</year>;<volume>11</volume>:<fpage>1141</fpage>&#x2013;<lpage>1148</lpage>.
                    <pub-id pub-id-type="pmid">29535538</pub-id>
                    <pub-id pub-id-type="doi">10.2147/OTT.S156792</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref20">
                <label>20</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wu</surname>
                            <given-names>ZF</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>MS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wong</surname>
                            <given-names>CS</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Propofol-based Total Intravenous Anesthesia Is Associated with Better Survival Than Desflurane Anesthesia in Colon Cancer Surgery.</article-title>
                    <source>

                        <italic toggle="yes">Anesthesiology.</italic>
</source>
                    <year>2018</year>;<volume>129</volume>(<issue>5</issue>):<fpage>932</fpage>&#x2013;<lpage>941</lpage>.
                    <pub-id pub-id-type="pmid">30028726</pub-id>
                    <pub-id pub-id-type="doi">10.1097/ALN.0000000000002357</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref21">
                <label>21</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Enlund</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Berglund</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Andreasson</surname>
                            <given-names>K</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>The choice of anaesthetic--sevoflurane or propofol--and outcome from cancer surgery: a retrospective analysis.</article-title>
                    <source>

                        <italic toggle="yes">Ups. J. Med. Sci.</italic>
</source>
                    <year>2014</year>;<volume>119</volume>(<issue>3</issue>):<fpage>251</fpage>&#x2013;<lpage>261</lpage>.
                    <pub-id pub-id-type="pmid">24857018</pub-id>
                    <pub-id pub-id-type="doi">10.3109/03009734.2014.922649</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref22">
                <label>22</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yap</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lopez-Olivo</surname>
                            <given-names>MA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dubowitz</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia.</article-title>
                    <source>

                        <italic toggle="yes">Can. J. Anaesth.</italic>
</source>
                    <year>2019</year>;<volume>66</volume>(<issue>5</issue>):<fpage>546</fpage>&#x2013;<lpage>561</lpage>.
                    <pub-id pub-id-type="pmid">30834506</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s12630-019-01330-x</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref23">
                <label>23</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Glaisyer</surname>
                            <given-names>HR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sury</surname>
                            <given-names>MR</given-names>
                        </name>
</person-group>:
                    <article-title>Recovery after anesthesia for short pediatric oncology procedures: propofol and remifentanil compared with propofol, nitrous oxide, and sevoflurane.</article-title>
                    <source>

                        <italic toggle="yes">Anesth. Analg.</italic>
</source>
                    <year>2005</year>;<volume>100</volume>(<issue>4</issue>):<fpage>959</fpage>&#x2013;<lpage>963</lpage>.
                    <pub-id pub-id-type="pmid">15781506</pub-id>
                    <pub-id pub-id-type="doi">10.1213/01.ANE.0000147667.06156.DF</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref24">
                <label>24</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Di</surname>
                            <given-names>N</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Guo</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ding</surname>
                            <given-names>N</given-names>
                        </name>
</person-group>:
                    <article-title>Effect of combined propofol-sevoflurane anesthesia on immune function in pediatric patients with acute lymphoblastic leukemia.</article-title>
                    <source>

                        <italic toggle="yes">Oncol. Lett.</italic>
</source>
                    <year>2019</year>;<volume>18</volume>(<issue>1</issue>):<fpage>35</fpage>&#x2013;<lpage>42</lpage>.
                    <pub-id pub-id-type="pmid">31289469</pub-id>
                    <pub-id pub-id-type="doi">10.3892/ol.2019.10316</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref25">
                <label>25</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Oduro-Dominah</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Brennan</surname>
                            <given-names>LJ</given-names>
                        </name>
</person-group>:
                    <article-title>Anaesthetic management of the child with haematological malignancy.</article-title>
                    <source>

                        <italic toggle="yes">Contin. Educ. Anaesth. Crit. Care Pain.</italic>
</source>
                    <year>2013</year>;<volume>13</volume>(<issue>5</issue>):<fpage>158</fpage>&#x2013;<lpage>164</lpage>.
                    <pub-id pub-id-type="doi">10.1093/bjaceaccp/mkt011</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref26">
                <label>26</label>
                <mixed-citation publication-type="other">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Cui</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gonzalez-Anton</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Li</surname>
                            <given-names>XM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>General anaesthetics reduce acute lymphoblastic leukaemia cell migration and homing 
                        <italic toggle="yes">in vitro</italic> and in vivo 
                        <italic toggle="yes">via</italic> CXCR4 and osteopontin mediated mechanisms.</article-title>
                    <year>2022</year>.
                    <pub-id pub-id-type="doi">10.5281/zenodo.7261294</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report187198">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.138230.r187198</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>M Maciocia</surname>
                        <given-names>Paul</given-names>
                    </name>
                    <xref ref-type="aff" rid="r187198a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-9757-8073</uri>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Yoon</surname>
                        <given-names>Jongwon</given-names>
                    </name>
                    <xref ref-type="aff" rid="r187198a2">2</xref>
                    <role>Co-referee</role>
                </contrib>
                <aff id="r187198a1">
                    <label>1</label>Department of Haematology, Cancer Institute, University College London, London, UK</aff>
                <aff id="r187198a2">
                    <label>2</label>Haematology, University College London, London, England, UK</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>21</day>
                <month>8</month>
                <year>2023</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 M Maciocia P and Yoon J</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport187198" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.125877.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This is an interesting yet somewhat incomplete article: as the authors note, general anaesthetics may have some potential anti-cancer properties. The authors investigated the effect of two commonly used anaesthetics, propofol and sevoflurane, in acute lymphoblastic leukaemia cells. Anaesthetics-treated ALL cells showed reduced migration and homing both in vitro and in vivo, and the authors suggested its mechanisms. This article is concise and well-written, and provides meaningful messages. I have only a few comments. 
                <list list-type="order">
                    <list-item>
                        <p>In Figure 4a, the authors tested the different concentrations of propofol and the different exposure time of sevoflurane. Is there a rationale for the propofol exposure time (ie. 6 hours)?</p>
                    </list-item>
                    <list-item>
                        <p>As the authors mentioned, the effects of general anaesthetic are thought to be reversible. How long does the anaesthetic effect last in ex vivo treated ALL cells? This is quite important for establishing if the phenomena reported here might have any clinical impact</p>
                    </list-item>
                    <list-item>
                        <p>The authors used isoflurane for anesthesia when imaging intravital microscopy. Is there any possibility that isoflurane interferes with propofol or sevoflurane?</p>
                    </list-item>
                    <list-item>
                        <p>In patients, the anaesthetics may affect the activity of normal cells as well. From the therapeutic point of view, do the authors think the reduced migration of ALL cells will outweigh the slowing of normal cell activity?</p>
                    </list-item>
                    <list-item>
                        <p>One cell line is not enough to draw conclusions &#x2013; the authors need to test multiple cell lines and primary B-ALL samples. This is the most critical point to accept for publication.</p>
                    </list-item>
                    <list-item>
                        <p>Its not at all clear what the functional consequences of these findings might be (I still don&#x2019;t really know if anaesthetics are potentially good or bad for patients from this study) and I would like to see this explored more, though appreciate this would be a much more in-depth paper.</p>
                    </list-item>
                </list> And here are my suggestions for minor revision: 
                <list list-type="order">
                    <list-item>
                        <p>It is unclear when intravital imaging was performed after ALL injection.</p>
                    </list-item>
                    <list-item>
                        <p>To represent multiple statistical significance between groups, it would be better to draw a line between comparing groups and put an asterisk mark over the line than ## symbol.</p>
                    </list-item>
                    <list-item>
                        <p>Introduction &#x2013; &#x2018;radiotherapy&#x2019; does not refer to diagnostic radiological procedures, there are also numerous typos</p>
                    </list-item>
                </list>
            </p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Yes</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Yes</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Yes</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Partly</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Partly</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Cellular immunotherapy, ALL, lymphoma.</p>
            <p>We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.</p>
        </body>
        <sub-article article-type="response" id="comment11009-187198">
            <front-stub>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>jiang</surname>
                            <given-names>cui</given-names>
                        </name>
                        <aff/>
                    </contrib>
                </contrib-group>
                <author-notes>
                    <fn fn-type="conflict">
                        <p>
                            <bold>Competing interests: </bold>No competing interests</p>
                    </fn>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>3</day>
                    <month>2</month>
                    <year>2024</year>
                </pub-date>
            </front-stub>
            <body>
                <p>Thanks this reviewer's insighful comment here is our point to point reply:&#x00a0;</p>
                <p> </p>
                <p> In Figure 4a, the authors tested the different concentrations of propofol and the different exposure time of sevoflurane. Is there a rationale for the propofol exposure time (ie. 6 hours)?</p>
                <p> </p>
                <p> 
                    <italic>
                        <underline>Reply: </underline>We did run a time course experiment with propofol at the beginning of the project i.e., 2 and 4 hours of propofol exposure, we only found 6 hours of propofol exposure to produce significant effect; hence 6 hours of propofol exposure is used </italic>
                </p>
                <p> 
                    <italic>&#x00a0;</italic>
                </p>
                <p> As the authors mentioned, the effects of general anaesthetic are thought to be reversible. How long does the anaesthetic effect last in ex vivo treated ALL cells? This is quite important for establishing if the phenomena reported here might have any clinical impact</p>
                <p> </p>
                <p> 
                    <italic>
                        <underline>Reply: </underline>As we have updated in the figure 4, propofol&#x2019;s effect seems to be short-lived given after 24 hours of recovery time, propofol stop having effect on cxcr4 expressions but sevoflurane seems to have potent reductive effect on the CXCR4 expression given after 24 hours of recovery time, CXCR4 expression is still reduced </italic>
                </p>
                <p> 
                    <italic>&#x00a0;</italic>
                </p>
                <p> The authors used isoflurane for anesthesia when imaging intravital microscopy. Is there any possibility that isoflurane interferes with propofol or sevoflurane?</p>
                <p> </p>
                <p> 
                    <italic>
                        <underline>Reply:</underline> This point has been discussed in the discussion section as systemic delivered isoflurane may need longer exposure time and more importantly repeated administrations to reach concentrations to significantly affect the experiment results as injected leukaemia cells were pre-treated ex-vivo before injections. In addition, if isoflurane had any effect on injected leukaemia cells, then such effect would affect sevoflurane group and propofol uniformly</italic>
                </p>
                <p> </p>
                <p> In patients, the anaesthetics may affect the activity of normal cells as well. From the therapeutic point of view, do the authors think the reduced migration of ALL cells will outweigh the slowing of normal cell activity?</p>
                <p> 
                    <italic>
                        <underline>Reply: </underline>Some studies have been carried out by our lab and others. And we found general anaesthetics have minimal toxicity against normal tissue. However, no one has studied whether general anaesthetics can reduce or interrupt normal bone marrow activity i.e., haematopoiesis given CXCR4 is an important&#x00a0; receptor for such activity. With this being said, for ALL patients, killing of leukaemia cells and re-shape bone marrow niche to be more hostile to ALL cells would likely outweigh the effect of general anaesthetics on normal bone marrow activity</italic>
                </p>
                <p> </p>
                <p> One cell line is not enough to draw conclusions &#x2013; the authors need to test multiple cell lines and primary B-ALL samples. This is the most critical point to accept for publication.</p>
                <p> 
                    <italic>
                        <underline>Reply: </underline>Reh data has been added in the manuscript per comment</italic>
                </p>
                <p> </p>
                <p> Its not at all clear what the functional consequences of these findings might be (I still don&#x2019;t really know if anaesthetics are potentially good or bad for patients from this study) and I would like to see this explored more, though appreciate this would be a much more in-depth paper.</p>
                <p> </p>
                <p> 
                    <italic>
                        <underline>Reply:</underline>Chemoresistance data has been added in the manuscript to show the functional consequence of general anaesthetics </italic> And here are my suggestions for minor revision: It is unclear when intravital imaging was performed after ALL injection.</p>
                <p> 
                    <italic>
                        <underline>Reply:</underline> Updated in the method section </italic>
                </p>
                <p> 
                    <italic>&#x00a0;</italic>
                </p>
                <p> To represent multiple statistical significance between groups, it would be better to draw a line between comparing groups and put an asterisk mark over the line than ## symbol.</p>
                <p> 
                    <italic>
                        <underline>Reply:</underline>This has been rectified in all figures </italic>
                </p>
                <p> 
                    <italic>&#x00a0;</italic>
                </p>
                <p> Introduction &#x2013; &#x2018;radiotherapy&#x2019; does not refer to diagnostic radiological procedures, there are also numerous typos</p>
                <p> 
                    <italic>
                        <underline>Reply: </underline>Added texts in introduction to minimise confusion </italic>
                </p>
            </body>
        </sub-article>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report158793">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.138230.r158793</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Yuki</surname>
                        <given-names>Koichi</given-names>
                    </name>
                    <xref ref-type="aff" rid="r158793a1">1</xref>
                    <xref ref-type="aff" rid="r158793a2">2</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-1312-585X</uri>
                </contrib>
                <aff id="r158793a1">
                    <label>1</label>Department of Anaesthesia, Harvard Medical School, Boston, MA, USA</aff>
                <aff id="r158793a2">
                    <label>2</label>Division of Cardiac Anesthesia, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>26</day>
                <month>1</month>
                <year>2023</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Yuki K</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport158793" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.125877.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This is the study that investigated the role of commonly used anesthetics propofol and sevoflurane in ALL cells, considering these drugs are often administered to patients with ALL. Authors found that anesthetics attenuated recruitment of ALL cells
                <italic> in vitro</italic> and 
                <italic>in vivo</italic>.</p>
            <p> </p>
            <p> A very interesting study by the group that heavily studies the role of anesthetics. I have one very simple comment.&#x00a0; 
                <list list-type="order">
                    <list-item>
                        <p>As authors mentioned in the introduction, patients with ALL often receive procedures. Those procedures are often short (&lt; 2 hours). Would you mind to elaborate your finding based on the duration of exposure?</p>
                    </list-item>
                    <list-item>
                        <p>What is the pathological significance of ALL cells recruited back to the bone marrow? Does this have any implication in the disease process? Authors found that ALL cells migrated less to the bone marrow. Does this effect last?</p>
                    </list-item>
                </list>
            </p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Yes</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Yes</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Yes</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Yes</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Anesthesia research</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
        <sub-article article-type="response" id="comment9397-158793">
            <front-stub>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>jiang</surname>
                            <given-names>cui</given-names>
                        </name>
                        <aff/>
                    </contrib>
                </contrib-group>
                <author-notes>
                    <fn fn-type="conflict">
                        <p>
                            <bold>Competing interests: </bold>N/A</p>
                    </fn>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>27</day>
                    <month>2</month>
                    <year>2023</year>
                </pub-date>
            </front-stub>
            <body>
                <p>Thank this reviewer for their kind comments</p>
                <p> </p>
                <p> Response</p>
                <p> </p>
                <p> 
                    <bold>Question 1:</bold>
                </p>
                <p> We did acknowledge the longer exposure time is a limitation of the study. We have put in the discussion section: &#x201c;
                    <italic>Clinical doses of general anaesthetics for invasive procedures in adult patients are generally lower and shorter in duration for such procedures.</italic>&#x201d; &#x00a0; &#x00a0; &#x00a0; &#x00a0; &#x00a0; &#x00a0;</p>
                <p> </p>
                <p> 6 hours exposure time was chosen because: 
                    <list list-type="order">
                        <list-item>
                            <p>We wish to do a proof-of-concept studies on whether long exposure time would yield significant results before designing shorter time period experiments given the how expensive it is to run such experiments.</p>
                        </list-item>
                        <list-item>
                            <p>Although the initial half-life of propofol and sevoflurane is very short and patients recover from anaesthesia within minutes, the terminal half-life of propofol and sevoflurane can be theoretically long (4-7 hours for propofol reference: 
                                <italic>Khurram Saleem Khan, FCAI FJFICMI, Ivan Hayes, FCAI FJFICMANZ, Donal J Buggy, MD MSc DME FRCPI FCAI FRCA, Pharmacology of anaesthetic agents I: intravenous anaesthetic agents,&#x00a0;Continuing Education in Anaesthesia Critical Care &amp; Pain, Volume 14, Issue 3, June 2014, Pages 100&#x2013;105</italic> and up to 20 hours for sevoflurane reference: 
                                <italic>Clin Pharmacokinet 1999 Jan; 36 (1). Page 19). </italic>Long terminal half life may&#x00a0;hypothetically give time for general anaesthetics to act on leukaemia cells</p>
                        </list-item>
                    </list> </p>
                <p> With all being said, we did perform in vitro experiments measuring cellular parameters for other parallel studies e.g. protetin expressions and in vitro functional assays with shorter time period i.e. 2 hour; we could see significant cellular changes following 2 hours exposure time of propofol and sevoflurane; we may publish those results in the near future</p>
                <p> </p>
                <p> 
                    <bold>Question 2:</bold>
                </p>
                <p> Recruitment of ALL to the bone marrow is the first step of the homing process which allow the disease to happen in this murine model &#x2013; given these mice are not genetically modified to have ALL genes. Reduction of recruitment of ALL cells to bone marrow translates into reduction in homing hence lower possibility of disease-causing cells in bone marrow.</p>
            </body>
        </sub-article>
    </sub-article>
</article>
